
Johnson & Johnson (J&J) suspended its plans of buying Takeda Pharmaceutical’s TachoSil on Friday, April 10. The American multinational corporation cited regulatory concerns for abandoning the deal.
Takeda Pharmaceutical is the largest drug manufacturer in Japan. Takeda had revealed in May 2019 that J&J’s subsidiary, Ethicon, wishes to buy its surgical patch that is used to control bleeding for £320 million (US$398.56 million).
Johnson & Johnson’s representative was reported commenting on Friday, “Ethicon and Takeda have mutually decided to terminate the TachoSil transaction, agreeing that it was the right decision given the regulators’ concerns.”
Chairman Joseph Simons of the Federal Trade Commission (FTC) released a statement earlier on Friday highlighting regulatory concerns regarding the J&J-Takeda deal. Simons said that the regulatory issues stem from the fact that J&J is the manufacturer of the only other fibrin sealant patch that is approved for use in the United States. J&J’s patch is available in the US by the name of Evarrest and is widely used during surgeries to control bleeding.
According to Simons’ email, “Staff had significant concerns about the likely anticompetitive effects and had recommended that the Commission block the transaction. Now that the deal has been abandoned, patients and surgeons will continue to benefit from competition.”
Full Content: Yahoo
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Court Order Temporarily Halts U.S. Consumer Financial Protection Bureau Layoffs
Feb 16, 2025 by
CPI
Nokia Poised to Gain EU Approval for $2.3 Billion Infinera Acquisition
Feb 16, 2025 by
CPI
Turkey Fines Frito-Lay in Antitrust Crackdown
Feb 16, 2025 by
CPI
Advances Bill to Strengthen Antitrust Enforcement Through AI
Feb 16, 2025 by
CPI
Intel Faces Potential Breakup as Broadcom and TSMC Explore Deals
Feb 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon